Alimera Sciences (ALIM) Given Media Impact Score of 0.17
News stories about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.2417530574128 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Edited Transcript of ALIM earnings conference call or presentation 2-Nov-17 1:00pm GMT (finance.yahoo.com)
- Investor’s Roundup (Intraday Analysis): Alimera Sciences Inc (NASDAQ: ALIM) – Alpha Beta Stock (alphabetastock.com)
- Alimera Sciences’ (ALIM) CEO Dan Myers on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Alimera Sciences (ALIM) versus Its Competitors Head to Head Review (americanbankingnews.com)
- Alimera Sciences, Inc. 2017 Q3 – Results – Earnings Call Slides (seekingalpha.com)
Several research firms have issued reports on ALIM. Cowen and Company reissued a “buy” rating and issued a $3.00 price objective on shares of Alimera Sciences in a research report on Tuesday, July 11th. HC Wainwright set a $5.00 price objective on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research cut shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ ALIM) traded down $0.02 on Monday, hitting $1.32. 169,155 shares of the stock traded hands, compared to its average volume of 225,292. Alimera Sciences has a 52-week low of $1.04 and a 52-week high of $1.72. The company has a debt-to-equity ratio of -0.72, a current ratio of 4.63 and a quick ratio of 4.51.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.